Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04696731
Title Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (TRAVERSE)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Allogene Therapeutics

renal cell carcinoma


ALLO-647 + Cyclophosphamide + Fludarabine


Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Recruiting Duarte California 91010 United States Details
UCLA Medical Center Recruiting Los Angeles California 90095 United States Details
Moffitt Cancer Center Recruiting Tampa Florida 33612 United States Details
Memorial Sloan Kettering Cancer Center Recruiting New York New York 10065 United States Details
Providence Portland Medical Center Recruiting Portland Oregon 97213 United States Details
MD Anderson Cancer Center Recruiting Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from for the field